|
1
|
Owens B: Melanoma. Nature. 515
(Suppl):S1092014. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mohammadpour A, Derakhshan M, Darabi H,
Hedayat P and Momeni M: Melanoma: Where we are and where we go. J
Cell Physiol. 234:3307–3320. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Little EG and Eide MJ: Update on the
current state of melanoma incidence. Dermatol Clin. 30:355–361.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ko JS: The immunology of melanoma. Clin
Lab Med. 37:449–471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hayward NK, Wilmott JS, Waddell N,
Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov
LB, Burke H, et al: Whole-genome landscapes of major melanoma
subtypes. Nature. 545:175–180. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wong CW, Fan YS, Chan TL, Chan AS, Ho LC,
Ma TK, Yuen ST and Leung SY; Cancer Genome Project, : BRAF and NRAS
mutations are uncommon in melanomas arising in diverse internal
organs. J Clin Pathol. 58:640–644. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fuchs Wightman F, Giono LE, Fededa JP and
de la Mata M: Target RNAs strike back on MicroRNAs. Front Genet.
9:4352018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Treiber T, Treiber N and Meister G:
Regulation of microRNA biogenesis and its crosstalk with other
cellular pathways. Nat Rev Mol Cell Biol. 20:5–20. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mumford SL, Towler BP, Pashler AL,
Gilleard O, Martin Y and Newbury SF: Circulating MicroRNA
biomarkers in melanoma: Tools and challenges in personalised
medicine. Biomolecules. 8:E212018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mirzaei H, Gholamin S, Shahidsales S,
Sahebkar A, Jaafari MR, Mirzaei HR, Hassanian SM and Avan A:
MicroRNAs as potential diagnostic and prognostic biomarkers in
melanoma. Eur J Cancer. 53:25–32. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu Y, Zhang HL, Wang QY, Chen MJ and Liu
LB: Overexpression of microRNA-612 restrains the growth, invasion,
and tumorigenesis of melanoma cells by targeting espin. Mol Cells.
41:119–126. 2018.PubMed/NCBI
|
|
14
|
Zhang J, Liu WL, Zhang L, Ge R, He F, Gao
TY, Tian Q, Mu X, Chen LH, Chen W and Li X: MiR-637 suppresses
melanoma progression through directly targeting P-REX2a and
inhibiting PTEN/AKT signaling pathway. Cell Mol Biol
(Noisy-le-grand). 64:50–57. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Panza E, Ercolano G, De Cicco P, Armogida
C, Scognamiglio G, Botti G, Cirino G and Ianaro A: MicroRNA-143-3p
inhibits growth and invasiveness of melanoma cells by targeting
cyclooxygenase-2 and inversely correlates with malignant melanoma
progression. Biochem Pharmacol. 156:52–59. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pfeffer SR, Yang CH and Pfeffer LM: The
role of miR-21 in cancer. Drug Dev Res. 76:270–277. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang H, Li J, Li G and Wang S: Effects of
celastrol on enhancing apoptosis of ovarian cancer cells via the
downregulation of microRNA21 and the suppression of the
PI3K/Akt-NF-κB signaling pathway in an in vitro model of ovarian
carcinoma. Mol Med Rep. 14:5363–5368. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mu Z and Sun Q: Cantharidin inhibits
melanoma cell proliferation via the miR21mediated PTEN pathway. Mol
Med Rep. 18:4603–4610. 2018.PubMed/NCBI
|
|
19
|
Wandler A, Riber-Hansen R, Hager H,
Hamilton-Dutoit SJ, Schmidt H, Nielsen BS, Stougaard M and
Steiniche T: Quantification of microRNA-21 and microRNA-125b in
melanoma tissue. Melanoma Res. 27:417–428. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mao XH, Chen M, Wang Y, Cui PG, Liu SB and
Xu ZY: MicroRNA-21 regulates the ERK/NF-κB signaling pathway to
affect the proliferation, migration, and apoptosis of human
melanoma A375 cells by targeting SPRY1, PDCD4, and PTEN. Mol
Carcinog. 56:886–894. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang HL, Si LB, Zeng A, Long F, Qi Z,
Zhao R and Bai M: MicroRNA-21 antisense oligonucleotide improves
the sensitivity of human melanoma cells to cisplatin: An in vitro
study. J Cell Biochem. 119:3129–3141. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bossi G: MKK3 as oncotarget. Aging (Albany
NY). 8:1–2. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huth HW, Albarnaz JD, Torres AA, Bonjardim
CA and Ropert C: MEK2 controls the activation of MKK3/MKK6-p38 axis
involved in the MDA-MB-231 breast cancer cell survival: Correlation
with cyclin D1 expression. Cell Signal. 28:1283–1291. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grimson A, Farh KK, Johnston WK,
Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting
specificity in mammals: Determinants beyond seed pairing. Mol Cell.
27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fattouh K, Ducroux E, Decullier E,
Kanitakis J, Morelon E, Boissonnat P, Sebbag L, Jullien D and
Euvrard S: Increasing incidence of melanoma after solid organ
transplantation: A retrospective epidemiological study. Transpl
Int. 30:1172–1180. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee JA: Current evidence about the causes
of malignant melanoma. Prog Clin Cancer. 6:151–161. 1975.PubMed/NCBI
|
|
28
|
Wikstrom JD, Lundeberg L, Frohm-Nilsson M
and Girnita A: Differences in cutaneous melanoma treatment and
patient satisfaction. PLoS One. 13:e02055172018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marcell Szasz A, Malm J, Rezeli M,
Sugihara Y, Betancourt LH, Rivas D, Gyorffy B and Marko-Varga G:
Challenging the heterogeneity of disease presentation in malignant
melanoma-impact on patient treatment. Cell Biol Toxicol. 39:1–14.
2019. View Article : Google Scholar
|
|
30
|
Rockberg J, Amelio JM, Taylor A, Jörgensen
L, Ragnhammar P and Hansson J: Epidemiology of cutaneous melanoma
in Sweden-Stage-specific survival and rate of recurrence. Int J
Cancer. 139:2722–2729. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baldari S, Ubertini V, Garufi A, D'Orazi G
and Bossi G: Targeting MKK3 as a novel anticancer strategy:
Molecular mechanisms and therapeutical implications. Cell Death
Dis. 6:e16212015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu Y, Song Y, Xiong Y, Wang X, Xu K, Han
B, Bai Y, Li L, Zhang Y and Zhou L: MicroRNA-21 (Mir-21) promotes
cell growth and invasion by repressing tumor suppressor PTEN in
colorectal cancer. Cell Physiol Biochem. 43:945–958. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lynch MP, Nawaz S and Gerschenson LE:
Evidence for soluble factors regulating cell death and cell
proliferation in primary cultures of rabbit endometrial cells grown
on collagen. Proc Natl Acad Sci USA. 83:4784–4788. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Broussard L, Howland A, Ryu S, Song K,
Norris D, Armstrong CA and Song PI: Melanoma cell death mechanisms.
Chonnam Med J. 54:135–142. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Miller FR: Immune mechanisms in the
sequential steps of metastasis. Crit Rev Oncog. 4:293–311.
1993.PubMed/NCBI
|
|
36
|
Scully OJ, Bay BH, Yip G and Yu Y: Breast
cancer metastasis. Cancer Genomics Proteomics. 9:311–320.
2012.PubMed/NCBI
|
|
37
|
Wu J, Zhang Y, Cheng R, Gong W, Ding T,
Zhai Q, Wang Y, Meng B and Sun B: Expression of
epithelial-mesenchymal transition regulatorsTWIST, SLUG and SNAIL
in follicular thyroid tumours may relate to widely invasive, poorly
differentiated and distant metastasis. Histopathology. 74:780–791.
2019. View Article : Google Scholar : PubMed/NCBI
|
